Page:United States Statutes at Large Volume 116 Part 3.djvu/396

From Wikisource
Jump to: navigation, search
This page needs to be proofread.

116 STAT. 1988 PUBLIC LAW 107-280—NOV. 6, 2002 Public Law 107-280 107th Congress An Act Nov. 6, 2002 To amend the Public Health Service Act to establish an Office of Rare Diseases [H R 4013] ^^ *^^ National Institutes of Health, and for other purposes. Be it enacted by the Senate and House of Representatives of Rare Diseases the United States of America in Congress assembled, Act of 2002. 42 USC 201 note. SECTION 1. SHORT TITLE. This Act may be cited as the "Rare Diseases Act of 2002". 42 USC 283h SEC. 2. FINDINGS AND PURPOSES. (a) FINDINGS.— Congress makes the following findings: (1) Rare diseases and disorders are those which affect small patient populations, typically populations smaller than 200,000 individuals in the United States. Such diseases and conditions include Huntington's disease, amyotrophic lateral sclerosis (Lou Gehrig's disease), Tourette syndrome, Crohn's disease, cystic fibrosis, cystinosis, and Duchenne muscular dystrophy. (2) For many years, the 25,000,000 Americans suffering from the over 6,000 rare diseases and disorders were denied access to effective medicines because prescription drug manufacturers could rarely make a profit from marketing drugs for such small groups of patients. The prescription drug industry did not adequately fund research into such treatments. Despite the urgent health need for these medicines, they came to be known as "orphan drugs" because no companies would commercialize them. (3) During the 1970s, an organization called the National Organization for Rare Disorders (NORD) was founded to provide services and to lobby on behalf of patients with rare diseases and disorders. NORD was instrumental in pressing Congress for legislation to encourage the development of orphan drugs. (4) The Orphan Drug Act created financial incentives for the research and production of such orphan drugs. New Federal programs at the National Institutes of Health and the Food and Drug Administration encouraged clinical research and commercial product development for products that target rare diseases. An Orphan Products Board was established to promote the development of drugs and devices for rare diseases or disorders. (5) Before 1983, some 38 orphan drugs had been developed. Since the enactment of the Orphan Drug Act, more than 220 new orphan drugs have been approved and marketed in the